Literature DB >> 12690587

Oral motor, communication, and nutritional status of children during intrathecal baclofen therapy: a descriptive pilot study.

Kristie F Bjornson1, John F McLaughlin, John D Loeser, Kim M Nowak-Cooperman, Mark Russel, Kathy A Bader, StarRina A Desmond.   

Abstract

OBJECTIVE: To describe the oral motor, communication, and nutritional status of children receiving intrathecal baclofen (ITB) therapy for spasticity of cerebral origin.
DESIGN: Observational cross-sectional design.
SETTING: Tertiary-care regional children's hospital. PARTICIPANTS: Thirty children with spasticity of cerebral origin receiving ITB therapy.
INTERVENTIONS: Not applicable. MAIN OUTCOME MEASURES: One interviewer administered a structured in-person interview tool designed for this pilot study, data from which were collapsed into 4 change categories: communication and speech, feeding and nutrition, oral motor function, and gastrointestinal function. Functional severity was ranked with the Gross Motor Function Classification System (GMFCS).
RESULTS: Speech: 10 improved (5 in GMFCS level V) and 2 worsened. Use of assistive technology to communicate: 6 improved (5 in GMFCS level V). Appetite: 10 improved (6 in GMFCS level V) and 4 worsened. Self-feeding: 9 improved (2 in GMFCS level III, 4 in level IV, 3 in level V) and 2 worsened. Saliva control: 10 improved (1 in GMFCS level III, 1 in level IV, 8 in level V) and 8 worsened. Cup drinking: 12 improved (5 in GMFCS level V) and 2 worsened. Indicates thirst: 9 improved (4 in GMFCS level IV, 5 in level V) and none worsened. Stool frequency: 8 improved (8 in GMFCS level V) and 14 worsened.
CONCLUSIONS: Some aspects of speech, communication, and saliva control seemed to have improved, with bowel movement frequency decreased in some children receiving ITB. Fewer changes in feeding and nutritional status were reported. On the basis of this pilot study, prospective management guidelines are proposed that relate objective outcome measures of oral motor function, communication, and nutrition to changes in spasticity with ITB.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12690587     DOI: 10.1053/apmr.2003.50030

Source DB:  PubMed          Journal:  Arch Phys Med Rehabil        ISSN: 0003-9993            Impact factor:   3.966


  5 in total

Review 1.  Intrathecal baclofen for childhood hypertonia.

Authors:  A Leland Albright
Journal:  Childs Nerv Syst       Date:  2007-06-29       Impact factor: 1.475

2.  Intrathecal baclofen pump for spasticity: an evidence-based analysis.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2005-05-01

3.  Intrathecal baclofen therapy in paediatrics: a study protocol for an Australian multicentre, 10-year prospective audit.

Authors:  Kirsty Stewart; Gavin Hutana; Megan Kentish
Journal:  BMJ Open       Date:  2017-06-21       Impact factor: 2.692

Review 4.  Intrathecal baclofen for treating spasticity in children with cerebral palsy.

Authors:  Monika J Hasnat; James E Rice
Journal:  Cochrane Database Syst Rev       Date:  2015-11-13

5.  Effects of Abnormal Oral Reflexes on Speech Articulation in Persian Speaking Children with Spastic Cerebral Palsy.

Authors:  Hooshang Dadgar; Mohammad Reza Hadian; Ortega Adriana Lira
Journal:  Iran J Child Neurol       Date:  2016
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.